Summary
IMvigor211 was a multicentre, phase 3 randomised controlled trial comparing atezolizumab, a PD-L1 inhibitor, against standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based regimens. As a major oncology trial published in The Lancet in 2017, this study evaluated whether immunotherapy offered clinical benefit over conventional chemotherapy in this difficult-to-treat population, contributing to the evidence base for checkpoint inhibitor use in bladder cancer.
UK applicability
Findings from this international trial are directly applicable to UK clinical practice, as atezolizumab and similar immunotherapies are evaluated by NICE for use within the NHS. Results would inform treatment algorithms for advanced urothelial carcinoma in UK oncology centres.
Key measures
Overall survival, progression-free survival, objective response rate, adverse events, and quality-of-life metrics (as typical for phase 3 oncology trials)
Outcomes reported
The study compared efficacy and safety of atezolizumab (an anti-PD-L1 immunotherapy) versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma. Primary endpoints as suggested by the trial design likely included overall survival, progression-free survival, and response rates.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.